Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 10/22/2014 AVERAGE SEVERITY GRADES[b]

Test Compound: Transgenic model evaluation (DES)

CAS Number: 56-53-1

Time Report Requested: 17:57:30

First Dose M/F: NA / NA

Lab: BAT

C Number: C97011G

Lock Date: 07/19/2001

Cage Range: ΑII

Date Range: ΑII

Reasons For Removal: ΑII

Removal Date Range: ΑII

Treatment Groups: ΑII

Study Gender: Both

PWG Approval Date NONE

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:57:30

Test Compound: Transgenic model evaluation (DES)

CAS Number: 56-53-1

Time Report Requested: 17:57:30

First Dose M/F: NA / NA

FVB/N Mouse MALE	0 UG/KG	480 UG/KG
Disposition Summary		
Animals Initially In Study	15	15
Early Deaths		
Moribund Sacrifice		2
Natural Death		2
Survivors		
Terminal Sacrifice	15	11
Animals Examined Microscopically	15	15
ALIMENTARY SYSTEM		
Liver	(15)	(15)
Basophilic Focus	1	
Centrilobular, Midzonal, Hypertrophy		14 [1.9]
Clear Cell Focus		1
Inflammation, Granulomatous	5 [1.0]	10 [1.0]
Necrosis, Focal		3 [2.0]
Vacuolization Cytoplasmic, Diffuse		1 [4.0]
Mesentery	(1)	(0)
Fat, Necrosis	1 [2.0]	
Stomach, Forestomach	(15)	(15)
Epithelium, Hyperplasia, Diffuse		3 [1.0]
CARDIOVASCULAR SYSTEM		
Blood Vessel	(1)	(3)
Heart	(15)	(15)
ENDOCRINE SYSTEM		
Adrenal Cortex	(15)	(15)
Zona Reticul, Hypertrophy	(/	15 [3.1]
Zona Reticul, Pigmentation		15 [3.1]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:57:30

Test Compound: Transgenic model evaluation (DES)

CAS Number: 56-53-1

Time Report Requested: 17:57:30

First Dose M/F: NA / NA

FVB/N Mouse MALE	0 UG/KG	480 UG/KG	
Zona Reticul, Syncytial Alteration		15 [3.1]	
Zona Reticul, Vacuolization Cytoplasmic		15 [3.1]	
Adrenal Medulla	(15)	(15)	
Pituitary Gland	(15)	(15)	
Cyst		1 [1.0]	
Pars Distalis, Cytoplasmic Alteration		15 [2.8]	
Pars Distalis, Hyperplasia		15 [2.8]	
Thyroid Gland	(15)	(15)	
Hyperplasia, Focal		1 [1.0]	
GENERAL BODY SYSTEM			
None			
GENITAL SYSTEM			
Coagulating Gland	(15)	(15)	
Metaplasia, Squamous		15 [4.0]	
Epididymis	(15)	(15)	
Degeneration	3 [3.0]	14 [2.2]	
Fibrosis		13 [1.0]	
Preputial Gland	(0)	(7)	
Atrophy		7 [2.1]	
Duct, Hyperplasia		7 [3.0]	
Prostate	(15)	(15)	
Atrophy		13 [3.1]	
Epithelium, Cytoplasmic Alteration	7 [1.0]		
Seminal Vesicle	(15)	(15)	
Atrophy		15 [4.0]	
Testes	(15)	(15)	
Germinal Epith, Atrophy	3 [1.7]	15 [2.6]	
Interstit Cell, Hypertrophy		15 [2.6]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:57:30

Test Compound: Transgenic model evaluation (DES)

CAS Number: 56-53-1

Time Report Requested: 17:57:30

First Dose M/F: NA / NA

FVB/N Mouse MALE	0 UG/KG	480 UG/KG	
Interstit Cell, Pigmentation		15 [2.6]	
Interstit Cell, Syncytial Alteration		14 [2.3]	
Interstit Cell, Vacuolization Cytoplasmic		15 [2.6]	
Rete Testes, Cyst	1 [3.0]		
HEMATOPOIETIC SYSTEM			
Lymph Node	(15)	(15)	
Lymph Node, Mandibular	(15)	(15)	
Hyperplasia, Lymphoid	2 [3.0]		
Lymph Node, Mesenteric	(15)	(15)	
Spleen	(15)	(15)	
Hematopoietic Cell Proliferation	2 [1.0]	8 [1.4]	
Lymph Follic, Atrophy		1 [3.0]	
Lymph Follic, Hyperplasia	3 [1.3]	3 [1.0]	
Thymus	(15)	(15)	
Atrophy		6 [2.3]	
INTEGUMENTARY SYSTEM			
Mammary Gland	(0)	(10)	
Hyperplasia		10 [2.1]	
Skin	(15)	(15)	
Dermis, SOA, Subcut Tiss, Edema		13 [1.1]	
Dermis, SOA, Subcut Tiss, Infiltration Cellular, Mononuclear Cl	1 [1.0]	12 [1.0]	
Epidermis, SOA, Hyperplasia	2 [1.0]	3 [1.0]	
Prepuce, Inflammation, Acute		1 [4.0]	
Prepuce, Inflammation, Suppurative		1 [4.0]	
SOA, Hyperkeratosis		12 [1.0]	
Skin, Control	(0)	(15)	
Hyperkeratosis		15 [1.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:57:30

Test Compound: Transgenic model evaluation (DES)

CAS Number: 56-53-1

Time Report Requested: 17:57:30

First Dose M/F: NA / NA

FVB/N Mouse MALE	0 UG/KG	480 UG/KG
MUSCULOSKELETAL SYSTEM		
None		
NERVOUS SYSTEM		
None		
RESPIRATORY SYSTEM		
Lung	(15)	(15)
Inflammation, Chronic, Focal	4 [1.0]	5 [1.0]
SPECIAL SENSES SYSTEM		
None		
URINARY SYSTEM		
Kidney	(15)	(15)
Casts Protein		1 [1.0]
Hydronephrosis		6 [3.0]
Inflammation, Chronic, Focal	1 [1.0]	
Nephropathy	1 [1.0]	
Renal Tubule, Cyst		1 [1.0]
Renal Tubule, Hyperplasia, Focal		1 [1.0]
Urinary Bladder	(0)	(3)
Cyst		3 [4.0]

^{***}END OF MALE DATA***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:57:30

Test Compound: Transgenic model evaluation (DES)

CAS Number: 56-53-1

Time Report Requested: 17:57:30

First Dose M/F: NA / NA

FVB/N Mouse FEMALE	0 UG/KG	480 UG/KG
Disposition Summary		
Animals Initially In Study	15	15
Early Deaths		
Natural Death	1	
Survivors		
Terminal Sacrifice	14	15
Animals Examined Microscopically	15	15
ALIMENTARY SYSTEM		
Liver	(15)	(15)
Centrilobular, Midzonal, Hypertrophy		13 [1.0]
Hematopoietic Cell Proliferation	4 [1.0]	5 [1.0]
Inflammation, Granulomatous	12 [1.0]	14 [1.0]
Vacuolization Cytoplasmic, Diffuse	1 [2.0]	2 [3.0]
Stomach, Forestomach	(15)	(15)
Epithelium, Hyperplasia, Diffuse	4 [1.3]	3 [1.7]
CARDIOVASCULAR SYSTEM		
Heart	(15)	(15)
ENDOCRINE SYSTEM		
Adrenal Cortex	(15)	(15)
Zona Reticul, Hypertrophy	15 [1.5]	15 [2.8]
Zona Reticul, Pigmentation	15 [1.5]	15 [2.8]
Zona Reticul, Syncytial Alteration	15 [1.5]	15 [2.8]
Zona Reticul, Vacuolization Cytoplasmic	15 [1.5]	15 [2.8]
Adrenal Medulla	(15)	(15)
Pituitary Gland	(15)	(15)
Cyst	3 [1.0]	
Pars Distalis, Cytoplasmic Alteration		15 [2.3]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:57:31

Test Compound: Transgenic model evaluation (DES)

CAS Number: 56-53-1

Time Report Requested: 17:57:31

First Dose M/F: NA / NA

FVB/N Mouse FEMALE	0 UG/KG	480 UG/KG
Pars Distalis, Degeneration, Focal	1 [1.0]	
Pars Distalis, Hyperplasia		15 [2.3]
Thyroid Gland	(15)	(15)
GENERAL BODY SYSTEM		
None		
GENITAL SYSTEM		
Clitoral Gland	(0)	(1)
Inflammation, Suppurative		1 [3.0]
Ovary	(15)	(15)
Corpus Luteum, Atrophy	1 [2.0]	15 [3.8]
Cyst	2 [1.5]	4 [1.8]
Oviduct	(15)	(15)
Epithelium, Hyperplasia		15 [1.3]
Uterus	(15)	(15)
Endometrium, Hyperplasia, Cystic	10 [1.1]	15 [1.9]
HEMATOPOIETIC SYSTEM		
Lymph Node	(13)	(13)
Lymph Node, Mandibular	(15)	(14)
Hyperplasia, Lymphoid	1 [3.0]	4 [2.5]
Lymph Node, Mesenteric	(15)	(15)
Spleen	(15)	(15)
Hematopoietic Cell Proliferation	1 [1.0]	10 [1.1]
Lymph Follic, Atrophy	1 [2.0]	
Thymus	(15)	(14)
Atrophy	1 [3.0]	2 [4.0]
INTEGUMENTARY SYSTEM		
Mammary Gland	(15)	(15)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:57:31

Test Compound: Transgenic model evaluation (DES)

CAS Number: 56-53-1

Time Report Requested: 17:57:31

First Dose M/F: NA / NA

FVB/N Mouse FEMALE	0 UG/KG	480 UG/KG
Hyperplasia	(4.4)	15 [1.4]
Skin	(14)	(15)
Dermis, SOA, Subcut Tiss, Edema		14 [1.0]
Dermis, SOA, Subcut Tiss, Infiltration Cellular, Mononuclear Cl		3 [1.0]
SOA, Hyperkeratosis		15 [1.1]
Skin, Control	(1)	(15)
Epidermis, Hyperplasia	1 [1.0]	
Hyperkeratosis		15 [1.0]
Parakeratosis		1 [1.0]
MUSCULOSKELETAL SYSTEM None		
NERVOUS SYSTEM None		
RESPIRATORY SYSTEM		
Lung	(15)	(15)
Alveolar Epith, Hyperplasia, Focal		1 [1.0]
Hyperplasia, Lymphoid, Focal		1 [1.0]
Inflammation, Chronic, Focal	5 [1.2]	4 [1.0]
SPECIAL SENSES SYSTEM None		
URINARY SYSTEM		
Kidney	(15)	(15)
Casts Protein	5 [1.0]	8 [1.0]
Hydronephrosis		1 [2.0]
Infarct	1 [2.0]	- -
Inflammation, Chronic Active	1 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:57:31

Test Compound: Transgenic model evaluation (DES)

CAS Number: 56-53-1

Time Report Requested: 17:57:31

First Dose M/F: NA / NA

Lab: BAT

FVB/N Mouse FEMALE	0 UG/KG	480 UG/KG
Nephropathy	1 [1.0]	3 [1.0]
Renal Tubule, Cyst		1 [1.0]
Renal Tubule, Hyperplasia, Focal	2 [1.0]	3 [1.0]

** END OF REPORT **

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)